Novacea, a biopharmaceutical company focused on in-licensing and commercializing novel therapies for the treatment of cancer, filed its IPO pricing terms with the SEC on Friday. The company plans to offer 6.25 million shares at $11 to $13 each. At the $12 midpoint, Novacea would have a market cap of $268 million. Bear Stearns and Cowen & Co. are the lead underwriters on the deal. The company has filed to be traded on the NASDAQ under the ticker NOVC.
